Achieve Life Sciences (NASDAQ:ACHV) Posts Earnings Results, Meets Expectations

Key Points

• Achieve Life Sciences reported a quarterly EPS of ($0.37), missing analyst expectations by $0.03.
• Following the earnings announcement, Achieve Life Sciences stock fell 5.3% to $2.50.
• Institutional ownership of the company stands at 33.52%, with AQR Capital Management recently acquiring a stake valued at approximately $32,000.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.37) EPS for the quarter, hitting analysts' consensus estimates of ($0.37), Zacks reports.

Achieve Life Sciences Trading Down 5.3%

Shares of NASDAQ:ACHV opened at $2.50 on Friday. The firm has a market cap of $86.73 million, a price-to-earnings ratio of -1.71 and a beta of 1.30. Achieve Life Sciences has a 12 month low of $1.84 and a 12 month high of $5.31. The company's fifty day simple moving average is $2.91 and its 200 day simple moving average is $2.84. The company has a quick ratio of 3.51, a current ratio of 3.51 and a debt-to-equity ratio of 0.85.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Achieve Life Sciences stock. AQR Capital Management LLC acquired a new stake in Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 11,802 shares of the biopharmaceutical company's stock, valued at approximately $32,000. Institutional investors own 33.52% of the company's stock.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.